Menopause & Nutrition: A Functional Nutritionist's Evidence-Based Guide

Menopause is not a disease, and it is not something that simply "happens to" women in their fifties. It is a profound endocrine transition — one that begins far earlier than most women are told, reshapes nearly every system in the body, and responds powerfully to how you eat, sleep, move, and manage stress. The frustrating truth is that most women arrive at perimenopause without a roadmap, are handed a symptom checklist by a well-meaning GP, and leave with either HRT or nothing, but rarely with the nutritional and metabolic framework that could make the difference.

The science has evolved significantly. What we now understand about the menopausal transition goes far beyond declining oestrogen. It involves the stress axis, insulin signalling, gut health, oestrogen metabolism, muscle physiology, and bone biology — all shifting simultaneously, all responsive to nutritional intervention. In my clinic, I see women in all stages of this transition, and the most consistent finding is that targeted nutrition, tested and applied with precision, changes the experience of menopause dramatically.

IN THIS ARTICLE:

• The hormonal changes across perimenopause, menopause, and post-menopause

• The HPA axis and why stress management is central to menopausal health

• Oestrogen metabolism via the liver and gut — and why this matters

• Muscle mass and insulin resistance: the protein imperative after 45

• Bone density beyond calcium: the roles of vitamin K2, magnesium, and boron

• Phytoestrogens: what the evidence actually shows

• Key nutrients and when HRT should be part of the conversation

Perimenopause, Menopause, and Post-Menopause: What Changes Hormonally at Each Stage

These three stages are frequently conflated, but they represent distinct hormonal environments requiring different nutritional emphases.

Perimenopause typically begins in the early-to-mid forties, though it can start as early as 38. The first hormone to decline meaningfully is progesterone, not oestrogen. Progesterone is produced by the corpus luteum after ovulation, and as ovarian reserve diminishes, cycles become anovulatory more frequently — meaning ovulation does not occur, progesterone is not produced, and oestrogen becomes relatively dominant. This is the hormonal backdrop for many perimenopausal symptoms: heavy or irregular periods, breast tenderness, anxiety, disrupted sleep, and mood instability.

Menopause is defined retrospectively as twelve consecutive months without a menstrual period, typically occurring between ages 45 and 55, with an average age of 51 in the UK. At this point, ovarian oestrogen production has declined dramatically. The adrenal glands and adipose tissue become the primary sites of oestrogen synthesis (producing oestrone, a weaker form), and testosterone also declines — affecting libido, energy, cognitive sharpness, and muscle mass.

Post-menopause is the phase from that twelve-month mark onwards. The absence of cycling oestrogen has long-term implications for bone density (which declines at its fastest rate in the first five years post-menopause), cardiovascular risk, cognitive function, and metabolic health. The nutritional priorities shift accordingly: from managing acute symptoms to building long-term systemic resilience.

Perimenopause can last anywhere from two to twelve years. If you are in your forties with irregular cycles, worsening PMS, anxiety, and sleep disruption, you are likely already in the transition — and nutritional support is appropriate now, not after your periods stop.

The HPA Axis in Menopause: Why Stress Management Is Non-Negotiable

The hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis share upstream regulatory architecture and are in direct competition for resources. During the menopausal transition, as ovarian oestrogen production declines, the adrenal glands are called upon to take up the hormonal slack — producing not only cortisol and DHEA but also contributing to peripheral oestrogen conversion.

When cortisol is chronically elevated — the predictable result of ongoing psychological, physiological, or metabolic stress — several things happen that directly worsen menopausal outcomes. First, cortisol competes with progesterone at the receptor level; high cortisol effectively blunts what little progesterone remains in the perimenopausal woman. Second, chronically elevated cortisol drives insulin resistance, promotes abdominal fat accumulation, disrupts sleep architecture, and impairs thyroid conversion. Third, the hot flush itself is mediated in part through the HPA axis: norepinephrine and the thermoregulatory centre in the hypothalamus are directly sensitised by declining oestrogen, and stress amplifies their reactivity.

What this means practically is that stress management is not a lifestyle nicety for menopausal women — it is a clinical intervention. Adequate sleep, regulated cortisol patterns, and HPA support through adaptogens such as ashwagandha (KSM-66 extract), phosphatidylserine, and magnesium glycinate are legitimate tools in the menopausal nutrition toolkit.

Hot flushes, insomnia, and anxiety in perimenopause are not purely oestrogen-deficiency symptoms — they are significantly mediated by the stress axis. A cortisol awakening response test and DUTCH hormone panel can reveal whether HPA dysregulation is compounding your transition.

Oestrogen Metabolism: Why Your Liver and Gut Health Shape Your Menopausal Experience

Oestrogen is not simply produced and then used — it is metabolised through a specific biochemical pathway that can either protect health or amplify risk, depending on how well the relevant organs are functioning.

The liver processes oestrogen through two phases of detoxification. In Phase 1, cytochrome P450 enzymes convert oestradiol into three metabolites: 2-hydroxyoestrone (considered the "good" pathway — anti-proliferative), 4-hydroxyoestrone (potentially genotoxic in excess), and 16-alpha-hydroxyoestrone (associated with increased oestrogen-sensitive tissue stimulation). In Phase 2, these metabolites are methylated, glucuronidated, or sulphated for excretion.

This is where the gut enters the picture. A specialised subset of gut bacteria — collectively the oestrobolome — produces an enzyme called beta-glucuronidase. In a healthy microbiome, beta-glucuronidase is present at low levels and oestrogen conjugates pass smoothly through the gut for excretion. In dysbiosis, beta-glucuronidase activity is elevated, and processed oestrogen is uncoupled from its excretory carrier and recirculated into the bloodstream.

Supporting the oestrobolome through fibre diversity, fermented foods, and targeted probiotic use is therefore a meaningful intervention at both ends of the menopausal spectrum.

If your menopausal symptoms include significant bloating, constipation, or a history of antibiotic use — your gut microbiome may be amplifying your hormonal imbalance. A comprehensive stool test is a worthwhile investigation before assuming the only solution is HRT.

Muscle Mass and Insulin Resistance After 45: The Protein Imperative

One of the most clinically significant — and most nutritionally modifiable — aspects of the menopausal transition is the simultaneous loss of muscle mass and rise in insulin resistance. Oestrogen has anabolic signalling properties in muscle tissue; as it declines, sarcopenia (age-related muscle loss) accelerates. Testosterone, which also declines during the menopausal transition, contributes further to reduced muscle protein synthesis.

This matters far beyond aesthetics. Skeletal muscle is the primary site of insulin-mediated glucose uptake. As muscle mass declines, the metabolic sink for blood glucose shrinks, and insulin resistance rises — even in women who have not changed their diet or exercise habits. This is the mechanistic explanation for the weight gain, particularly abdominal adiposity, that so many perimenopausal women experience despite doing "nothing differently."

The nutritional response is clear: protein intake must increase significantly from mid-life. Current evidence supports a target of 1.6–2.2 g of protein per kilogram of body weight per day for menopausal women, distributed across meals to maximise muscle protein synthesis. This is substantially higher than standard dietary recommendations and is rarely met without intentional planning.

Resistance training is the essential partner to adequate protein; neither works optimally without the other. The combination of progressive resistance exercise and leucine-sufficient protein intake is the most evidence-based intervention available for preserving metabolic health through the menopausal transition.

The shift to abdominal weight gain in perimenopause is not primarily about eating more — it is about declining oestrogen reducing muscle insulin sensitivity. Increasing protein intake and beginning resistance training are among the highest-leverage interventions you can make at this stage.

Bone Density: Beyond Calcium

The bone-building matrix requires a team of micronutrients. Vitamin D3 is essential for calcium absorption and bone mineralisation, and deficiency is endemic at northern latitudes; the target serum 25-OH vitamin D level for bone protection is 75–100 nmol/L, which requires supplementation for most people in the UK. But vitamin D without vitamin K2 (specifically the MK-7 form) means calcium absorbed from the gut may be deposited in soft tissues rather than directed to bone. Vitamin K2 activates osteocalcin (which binds calcium into bone matrix) and matrix Gla-protein (which inhibits vascular calcification).

Magnesium is required for the conversion of vitamin D to its active form, for osteoblast function, and for the regulation of parathyroid hormone, which governs calcium homeostasis. Boron is a trace mineral with underappreciated importance: it influences the metabolism of vitamin D and oestrogen, reduces urinary calcium loss, and supports osteocalcin production. Dietary sources include prunes, raisins, avocado, and nuts; supplementation at 3–6 mg daily is reasonable in post-menopausal women.

If your bone health protocol consists only of calcium and vitamin D, it is incomplete. Vitamin K2 (MK-7), magnesium, boron, and adequate protein — which provides the collagen matrix on which calcium is deposited — are equally important components of a comprehensive bone-building strategy.

Phytoestrogens: What the Evidence Actually Shows

Phytoestrogens are plant-derived compounds that bind to oestrogen receptors, primarily oestrogen receptor beta (ERβ), with much lower affinity than endogenous oestradiol. The main classes are isoflavones (found in soy, red clover, and legumes), lignans (found in flaxseed, sesame, and wholegrains), and coumestans (found in alfalfa and clover sprouts).

The most robust evidence relates to isoflavones — specifically genistein and daidzein — at doses of 40–80 mg daily, which have been shown in multiple randomised controlled trials to reduce hot flush frequency by 20–45% compared to placebo. The benefit is most pronounced in women who are "equol producers" — those whose gut bacteria can convert daidzein to equol, a more potent oestrogenic metabolite.

Concerns about soy and breast cancer risk have been largely addressed in prospective studies, which show that whole soy foods do not increase and may modestly reduce breast cancer risk. Highly processed soy isolates are a different matter and should be used with more caution.

Soy consumed as whole food — tofu, tempeh, edamame, miso — is not the same as soy protein isolate. The fermented forms (tempeh, miso) have added benefits for gut health and equol conversion. Two to four servings of whole soy foods weekly is a reasonable and well-evidenced dietary target for symptom support.

Key Nutrients & Supplements

Magnesium glycinate or malate: 300–400 mg daily, evening. Supports sleep, cortisol regulation, muscle relaxation, and bone mineralisation.

Vitamin D3 with K2 (MK-7): D3 2,000–4,000 IU daily with K2 100–200 mcg. Test serum levels before supplementing high-dose D3.

Omega-3 fatty acids (EPA/DHA): 2–3 g daily from high-quality triglyceride-form fish oil. Anti-inflammatory, supports mood, cognitive function, and cardiovascular health.

Ashwagandha (KSM-66): 300–600 mg daily. Adaptogen with the strongest clinical evidence for HPA regulation, cortisol reduction, and sleep improvement in perimenopausal women.

B vitamin complex (methylated): B6 (P5P), methylfolate, and methylcobalamin support HPA function, neurotransmitter synthesis, and methylation of oestrogen metabolites.

Isoflavones or whole soy foods: 40–80 mg isoflavones daily for hot flush reduction. Prioritise food sources; use supplements if dietary intake is low.

Collagen peptides: 10–15 g daily. Supports bone matrix, joint health, and skin integrity.

Boron: 3–6 mg daily in post-menopausal women. Supports oestrogen metabolism, bone density, and calcium retention.

Frequently Asked Questions

Q: I am 44 and still having regular periods but feel awful — can I really be in perimenopause?

Yes, absolutely. Perimenopause is defined by the hormonal changes accompanying the menopausal transition, not by cycle irregularity alone. Declining progesterone can begin in the early forties while cycles remain superficially regular. Symptoms including worsening PMS, increased anxiety, night sweats, breast tenderness, and changing energy patterns are consistent with early perimenopause even with regular menstruation. Testing FSH, LH, AMH, and a full hormonal panel can provide clarity.

Q: Should I take HRT? What is the current thinking?

The evidence on HRT has shifted substantially since the initial Women's Health Initiative (WHI) study. Current NICE guidance states that for women under 60 or within ten years of menopause onset, the benefits of HRT outweigh the risks for most women. Body-identical HRT (oestradiol patches or gel with micronised progesterone) has a more favourable risk profile than older synthetic formulations. The decision should be made individually with a menopause specialist, with nutritional foundations in place regardless.

Q: My bone scan shows early osteopenia — what should I prioritise?

The priorities are: vitamin D3 optimisation (test and target 75–100 nmol/L), vitamin K2 (MK-7) supplementation, adequate protein intake (1.6–2.0 g/kg/day), magnesium, and progressive resistance training. Calcium from dietary sources is preferable to supplementation, which carries a small but documented cardiovascular risk at high doses. Reassess with DEXA scan after twelve to eighteen months of intervention.

Q: Does alcohol affect menopausal symptoms significantly?

Yes, and it is one of the most modifiable factors. Alcohol disrupts sleep architecture, elevates cortisol, impairs liver oestrogen metabolism, increases hot flush frequency, and raises breast cancer risk. Even moderate consumption — two or more units daily — significantly worsens symptom burden. Reducing alcohol is among the most impactful dietary changes for many perimenopausal women.

When to Seek Medical Investigation

Seek assessment from a menopause specialist or your GP if:

• Your perimenopausal or menopausal symptoms are significantly affecting quality of life, work, sleep, or mental health

• You have unexplained bone loss on DEXA scan, or a personal or strong family history of osteoporosis

• You have significant cardiovascular risk factors emerging — new hypertension, dyslipidaemia, or impaired fasting glucose

• You are experiencing significant mood disturbance, including depression or anxiety, that is not responding to lifestyle measures

• You have a premature menopause (before age 40) or early menopause (40–45), which requires specialist management

Work With a Functional Nutritionist for Menopause

The menopausal transition is not something to endure — it is something to navigate with the right information, the right testing, and a plan built for your specific hormonal picture. In my clinic I work with women at every stage of the transition, using comprehensive hormone testing, targeted nutrition, and an integrative approach that works alongside your medical team.

Book your consultation →

Scientific References

1. Hillard, T., Abernathy, K., Hamoda, H., et al. (2023). Management of the Menopause. British Menopause Society. 6th edition.

2. Stearns, V., Ullmer, L., López, J. F., et al. (2002). Hot flushes. The Lancet, 360(9348), 1851–1861.

3. Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., et al. (2020). Menopausal hormone therapy and osteoporosis. Osteoporosis International, 31(12), 2271–2286.

4. Setchell, K. D. R., & Lydeking-Olsen, E. (2003). Dietary phytoestrogens and their effect on bone. American Journal of Clinical Nutrition, 78(3 Suppl), 593S–609S.

5. Messina, M. (2016). Soy and health update: Evaluation of the clinical and epidemiologic literature. Nutrients, 8(12), 754.

6. Baber, R. J., Panay, N., & Fenton, A. (2016). IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 19(2), 109–150.